In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations

Vaccine

Volumn 31, Issue 42, 2013, Pages 4812-4819

  Scherließ, Regina ^a   Buske, Simon ^a   Young, Katherine ^b   Weber, Benjamin ^c   Rades, Thomas ^b   Hook, Sarah ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

C57Bl 6 mice; Contaminants; Degree of deacetylation; Local depot; Molecular weight; Ovalbumin; Viscosity

Indexed keywords

ADJUVANT; CHITOCLEAR FG 95; CHITOPHARM S; CHITOSAN; CYTOKINE; ENDOTOXIN; INTERLEUKIN 2; OVALBUMIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DEACETYLATION; DRUG FORMULATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; IN VIVO STUDY; LIGHT SCATTERING; MASS IMMUNIZATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SMALLPOX; SPRAY DRYING; VACCINATION; VACCINE PRODUCTION; VISCOSITY;

C57BL/6 MICE; CONTAMINANTS; DEGREE OF DEACETYLATION; LOCAL DEPOT; MOLECULAR WEIGHT; OVALBUMIN; VISCOSITY;

ACETYLATION; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHITOSAN; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; VACCINES; VISCOSITY;

EID: 84884210574     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.081     Document Type: Article

References (48)

1. Bramwell V.W., Perrie Y. The rational design of vaccines. Drug Discovery Today 2005, 10(22):1527-1534.
2. Scherließ R. Delivery of antigens used for vaccination - recent advances and challenges. Therapeutic Delivery 2011, 2(10):1351-1368.
3. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. International Journal of Pharmaceutics 2008, 364:272-280.
4. Singh M., ÓHagan D. Recent advances in vaccine adjuvants. Pharmaceutical Research 2002, 19(6):715-728.
5. Saupe A., McBurney W.T., Rades T., Hook S. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opinion Drug Delivery 2006, 3(3):345-354.
6. Ribeiro C.M.S., Schijns V.E.J.C. Immunology of vaccine adjuvants. Vaccine adjuvants 2010, 1-14. Springer Science+Business Media, LCC, New York. G. Davies (Ed.).
7. Ott G. The adjuvant MF59: the 1998 perspective, clinical performance and mechanism of action. Research in Immunology 1998, 149:25-27.
8. Chadwick S., Kriegel C., Amiji M.M. Delivery strategies to enhance mucosal vaccination. Expert Opinion on Biological Therapy 2009, 9(4):427-440.
9. Malyala P., Singh M. Micro/nanoparticle adjuvants: preparation and formulation with antigens. Vaccine adjuvants 2010, 91-101. Springer Science+Business Media, LCC, New York. G. Davies (Ed.).
10. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. PNAS 2009, 106(3):870-875.
11. Foged C., Hansen J., Agger E.M. License to kill: formulation requirements for optimal priming of CD8+ CTL responses with particulate vaccine delivery systems. European Journal of Pharmaceutical Sciences 2012, 45:482-491.
12. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. Journal of Pharmaceutical Sciences 2009, 98(4):1278-1316.
13. Sharma S., Mukkur T.K., Benson H.A., Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. Journal of Pharmaceutical Sciences 2009, 98(3):812-843.
14. Boonyo W., Junginger H.E., Waranuch N., Polnok A., Pitaksuteepong T. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. Journal of Controlled Release 2007, 121:168-175.
15. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan for mucosal vaccination. Advanced Drug Delivery Reviews 2001, 52:139-144.
16. Jabbal-Gill I., Fisher A.N., Rappuolit R., Davis S.S., Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998, 16(20):2039-2046.
17. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Advanced Drug Delivery Reviews 2001, 51:81-96.
18. Gordon S., Saupe A., McBurney W.T., Rades T., Hook S. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. Journal of Pharmacy and Pharmacology 2008, 60:1591-1600.
19. Gordon S., Teichmann E., Young K., Finnie K., Rades T., Hook S. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery. European Journal of Pharmaceutical Sciences 2010, 41:360-368.
20. Ghendon Y., Markushin S., Visiliev Y., Akopova I., Koptiaeva I., Krivtsov G., et al. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. Journal of Medical Virology 2009, 81:494-506.
21. Soane R.J., Hinchcliffe M., Davis S.S., Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. International Journal of Pharmaceutics 2001, 217(April (1/2)):183-191.
22. Davies S.S., Illum L. Absorption enhancers for nasal drug delivery. Clinical Pharmacokinetics 2003, 42(13):1107-1128.
23. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan and its derivatives in mucosal drug and vaccine delivery. European Journal of Pharmaceutical Sciences 2001, 14:201-207.
24. da Silva C.A., Chalouni C., Williams A., Hartl D., Lee C.G.J.A.E. Chitin as a size-dependent regulator of macrophage TNF and IL-10 production. Journal of Immunology 2009, 182:3573-3582.
25. Hsu T.-L., Cheng S.-C., Yang W.-B., Chin S.-W., Chen B.-H., Huang M.-T., et al. Profiling carbohydrate-receptor interaction with recombinant innate immunity receptor-Fc fusion proteins. The Journal of Biological Chemistry 2009, 284(50):34479-34489.
26. Muzzarelli R.A.A. Chitins and chitosans as immunoadjuvants and non-allergenic drug carriers. Marine Drugs 2010, 8:292-312.
27. Aranaz I., Mengíbar M., Harris R., Paños I., Miralles B., Acosta N., et al. Functional characterization of chitin and chitosan. Current Chemical Biology 2009, 3:203-230.
28. Bueter C.L., Lee C.K., Rathinam V.A.K., Healy G.J., Taron C.H., Specht C.A., et al. Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis. Journal of Biological Chemistry 2011, 286(41):35447-35455.
29. Lertsutthiwong P., How N.C., Chandrkrachang S., Stevens W.F. Effect of chemical treatment on the characteristics of shrimp chitosan. Journal of Metals, Materials and Minerals 2002, 12:11-18.
30. de Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends in Immunology 2007, 28(11):482-490.
31. Wang W., Singh S.K., Li N., Toler M.R., King K.R., Nema S. Immunogenicity of protein aggregates - concerns and realities. International Journal of Pharmaceutics 2012, 431:1-11.
32. 1H NMR method for the determination of the degree of deacetylation of chitosan. Journal of Pharmaceutical and Biomedical Analysis 2003, 32:1149-1158.
33. Wu H. Correlations between the Rayleigh ratio and the wavelength for toluene and benzene. Chemical Physics 2010, 367:44-47.
34. Nguyen S., Hisiger S., Jolicoeur M., Winnik F.M., Buschmann M.D. Fractionation and characterization of chitosan by analytical SEC and 1H NMR after semi-preparative SEC. Carbohydrate Polymers 2009, 75:636-645.
35. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 1994, 76:17-27.
36. Barnden M.J., Allison J., Heath W.R., Carbone F.R. Defective TCR expression in transgenic mice constructed using cDNA-based a- and b-chain genes under the control of heterologous regulatory elements. Immunology and Cell Biology 1998, 76:34-40.
37. Pettini E., Ciabattini A., Pozzi G., Medaglini D. Adoptive transfer of transgenic T cells to study mucosal adjuvants. Methods 2009, 49:340-345.
38. McBurney W.T., Lendemans D.G., Myschik J., Hennessy T., Rades T., Hook S. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine 2008, 26:4549-4556.
39. de Temmerman M.-L., Rejman J., Demeester J., Irvine D.J., Gander B., de Smedt S.C. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discovery Today 2011, 16(13/14):569-582.
40. Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles for nasal vaccination. Advanced Drug Delivery Reviews 2009, 61:140-157.
41. Cruz L.J., Tacken P.J., Fokkink R., Joosten B., Stuart M.C., Albericio F., et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. Journal of Controlled Release 2010, 144:118-126.
42. Oussoren C., Zuidema J., Crommelin D.J.A., Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochimica et Biophysica Acta 1997, 1328:261-272.
43. Nishimura K., Nishimura S.-I., Nishi N., Numata F., Tone Y., Tokura S., et al. Adjuvant activity of chitin derivatives in mice and guinea-pigs. Vaccine 1985, 3:379-384.
44. Neimert-Andersson T., Hällgren A.-C., Andersson M., Langebäck J., Zettergren L., Nilsen-Nygaard J., et al. Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine 2011, 29:8965-8973.
45. Nishimura K., lshlhara C., Ukel S., Tokura S., Azuma I. Stimulation of cytokine production in mice using deacetylated chitin. Vaccine 1986, 4:151-156.
46. Gratton S.E.A., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proceedings of the National Academy of Science (PNAS) 2008, 105(33):11613-11618.
47. Foged C., Brodin B., Frokjaer S., Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. International Journal of Pharmaceutics 2005, 298:315-322.
48. Amidi M., Mastrobattista E., Jiskoot W., Hennink W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Advanced Drug Delivery Reviews 2010, 62:59-82.